StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
19
Publishing Date
2023 - 01 - 09
1
2022 - 08 - 23
1
2022 - 05 - 23
1
2022 - 04 - 27
1
2022 - 02 - 25
2
2022 - 02 - 14
1
2022 - 02 - 03
1
2022 - 01 - 10
1
2021 - 11 - 17
1
2021 - 10 - 27
1
2021 - 10 - 05
1
2021 - 09 - 09
1
2021 - 07 - 07
1
2021 - 05 - 27
1
2021 - 05 - 11
1
2021 - 03 - 11
1
2021 - 03 - 10
1
2020 - 12 - 16
1
Sector
Health technology
19
Tags
Antibody
1
Application
1
Approval
3
Authorization
1
Bioscience
1
Biotechnology
1
China
1
Chmp
1
Disease
1
Drug
1
Enroll
1
Europe
1
Ev
1
Fda
2
Fda approval
1
Fda-approvals
1
Global
1
Granted
1
Health
1
Israel
1
Ketamine
1
Lancet
1
License
1
Long term
1
Market
1
Mergers-and-acquisitions
1
Migraine
13
Muscular atrophy
1
N/a
5
Nurtec
1
Order
1
Pharm-country
6
Pharmaceutical
1
Phase 1
1
Phase 1b
1
Platform
1
Positive
2
Product-news
1
Regulatory
1
Report
2
Research
2
Results
1
Review
1
Therapy
2
Topline
1
Topline results
1
Treatment
17
Trial
2
Vydura
1
Entities
3m company
21
Abbott laboratories
60
Abbvie inc.
121
Accuray incorporated
21
Adamis pharmaceuticals corporation
19
Adial pharmaceuticals, inc
22
Alnylam pharmaceuticals, inc.
38
Amgen inc.
47
Arcutis biotherapeutics, inc.
25
Arrowhead pharmaceuticals, inc.
21
Astellas pharma inc
51
Astrazeneca plc
52
Bausch health companies inc.
36
Biogen inc.
42
Biohaven pharmaceutical holding company ltd.
19
Bioxcel therapeutics, inc.
20
Boston scientific corporation
21
Brainsway ltd.
41
Bridgebio pharma, inc.
20
Bristol-myers squibb company
94
Cns pharmaceuticals, inc.
26
Coherus biosciences, inc.
28
Compass pathways plc
20
Ecolab inc.
47
Eli lilly and company
180
Fortress biotech, inc.
27
Gilead sciences, inc.
50
Glaxosmithkline plc
103
Hoth therapeutics, inc.
24
Incyte corporation
77
Intellia therapeutics, inc.
32
Jazz pharmaceuticals plc
20
Johnson & johnson
208
Karyopharm therapeutics inc.
33
Koninklijke philips n.v.
21
Medicinova, inc.
24
Medtronic plc
46
Merck & company, inc.
65
Moleculin biotech, inc.
28
Novartis ag
144
Novo nordisk a/s
37
Nrx pharmaceuticals inc
20
Orange
87
Perrigo company
21
Pfizer, inc.
74
Reata pharmaceuticals, inc.
28
Regeneron pharmaceuticals, inc.
57
Regenxbio inc.
25
Sanofi
293
Sorrento therapeutics, inc.
37
Takeda pharmaceutical company limited
53
Teleflex incorporated
21
Teva pharmaceutical industries ltd
79
Tg therapeutics, inc.
24
Tonix pharmaceuticals holding corp.
32
Ultragenyx pharmaceutical inc.
25
Verrica pharmaceuticals inc.
23
Vertex pharmaceuticals incorporated
27
Viatris inc.
46
Xylem inc.
35
Symbols
BHVN
19
IONS
1
NVS
1
NVSEF
1
PFE
4
PTCT
1
SRRK
1
Exchanges
Nasdaq
1
Nyse
19
Crawled Date
2023 - 01 - 09
1
2022 - 08 - 23
1
2022 - 05 - 23
1
2022 - 04 - 27
1
2022 - 02 - 25
2
2022 - 02 - 14
1
2022 - 02 - 03
1
2022 - 01 - 10
1
2021 - 11 - 17
1
2021 - 10 - 27
1
2021 - 10 - 05
1
2021 - 09 - 09
1
2021 - 07 - 07
1
2021 - 05 - 27
1
2021 - 05 - 11
1
2021 - 03 - 11
1
2021 - 03 - 10
1
2020 - 12 - 16
1
Crawled Time
06:00
1
12:00
6
12:15
1
12:20
1
12:30
1
13:00
2
14:00
3
14:30
1
15:00
1
22:00
1
22:03
1
Source
www.biospace.com
14
www.prnewswire.com
5
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
treatment
entities :
Biohaven pharmaceutical holding company ltd.
save search
Global Spinal Muscular Atrophy Treatment Market Report 2022: Sector to Reach $11.4 Billion by 2028 at a 17.8% CAGR
Published:
2023-01-09
(Crawled : 15:00)
- prnewswire.com
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
|
24.84%
|
O:
3.12%
H:
0.0%
C:
-2.55%
PFE
A
|
$25.39
-0.12%
-0.12%
36M
|
Health Technology
|
-50.08%
|
O:
-1.71%
H:
0.42%
C:
-3.32%
NVS
|
$92.57
-0.55%
0.0%
910K
|
Health Technology
|
0.86%
|
O:
0.76%
H:
0.26%
C:
-3.27%
BHVN
|
News
0 d
|
$42.16
-4.25%
0.85%
3.7M
|
Health Technology
|
203.95%
|
O:
0.35%
H:
9.67%
C:
3.25%
SRRK
A
|
$13.96
1.9%
1.86%
860K
|
Health Technology
|
46.37%
|
O:
1.5%
H:
2.42%
C:
-0.11%
PTCT
|
$24.71
-1.79%
-1.82%
820K
|
Health Technology
|
-36.03%
|
O:
0.1%
H:
10.44%
C:
5.66%
IONS
|
$40.81
-0.24%
-0.25%
990K
|
Health Technology
|
0.96%
|
O:
-0.17%
H:
0.84%
C:
-7.91%
treatment
global
report
market
muscular atrophy
Freedom Biosciences Emerges from Stealth with $10.5 Million Seed Financing to Develop Next-Generation Ketamine and Psychedelic-based Mental Health Treatments
Published:
2022-08-23
(Crawled : 12:20)
- biospace.com/
BHVN
|
News
0 d
|
$42.16
-4.25%
0.85%
3.7M
|
Health Technology
|
-70.37%
|
O:
0.32%
H:
0.0%
C:
-0.3%
ketamine
health
US FDA Accepts for Review Biohaven's New Drug Application (NDA) Filing of Intranasal Zavegepant for the Acute Treatment of Migraine
Published:
2022-05-23
(Crawled : 12:00)
- prnewswire.com
BHVN
|
News
0 d
|
$42.16
-4.25%
0.85%
3.7M
|
Health Technology
|
-68.97%
|
O:
0.25%
H:
1.91%
C:
0.92%
treatment
fda
drug
application
review
migraine
Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine
Published:
2022-04-27
(Crawled : 12:00)
- biospace.com/
PFE
A
|
$25.39
-0.12%
-0.12%
36M
|
Health Technology
|
-48.43%
|
O:
-0.37%
H:
1.63%
C:
1.28%
BHVN
|
News
0 d
|
$42.16
-4.25%
0.85%
3.7M
|
Health Technology
|
-59.5%
|
O:
-4.64%
H:
3.6%
C:
0.93%
vydura
treatment
granted
migraine
authorization
Biohaven and Pfizer Receive Positive CHMP Opinion for Migraine Treatment
Published:
2022-02-25
(Crawled : 13:00)
- biospace.com/
PFE
A
|
$25.39
-0.12%
-0.12%
36M
|
Health Technology
|
-44.65%
|
O:
-0.02%
H:
0.0%
C:
0.0%
BHVN
|
News
0 d
|
$42.16
-4.25%
0.85%
3.7M
|
Health Technology
|
-67.22%
|
O:
-4.17%
H:
0.0%
C:
0.0%
treatment
migraine
positive
chmp
Biohaven Acquires Kv7 Ion Channel Platform for the Treatment of Epilepsy and Other Neurologic Disorders From Channel Biosciences, a Subsidiary of Knopp Biosciences
Published:
2022-02-25
(Crawled : 13:00)
- biospace.com/
BHVN
|
News
0 d
|
$42.16
-4.25%
0.85%
3.7M
|
Health Technology
|
-67.22%
|
O:
-4.17%
H:
0.0%
C:
0.0%
treatment
order
bioscience
platform
Biohaven and Pfizer Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea
Published:
2022-02-14
(Crawled : 12:30)
- biospace.com/
PFE
A
|
$25.39
-0.12%
-0.12%
36M
|
Health Technology
|
-49.94%
|
O:
-1.89%
H:
1.36%
C:
-0.04%
BHVN
|
News
0 d
|
$42.16
-4.25%
0.85%
3.7M
|
Health Technology
|
-67.47%
|
O:
0.27%
H:
2.86%
C:
1.95%
treatment
trial
migraine
china
topline results
positive
results
topline
NURTEC® ODT When Taken as an Acute Treatment for Migraine Reduces Monthly Migraine Days: Expanded Data from Long Term Treatment Published in Cephalalgia Reports
Published:
2022-02-03
(Crawled : 14:00)
- biospace.com/
BHVN
|
News
0 d
|
$42.16
-4.25%
0.85%
3.7M
|
Health Technology
|
-67.67%
|
O:
-5.9%
H:
2.59%
C:
2.26%
nurtec
treatment
long term
migraine
report
Biohaven Enters Exclusive License and Research Collaboration Agreement with KU Leuven to Advance First-in-Class TRPM3 Antagonists for the Treatment of Pain
Published:
2022-01-10
(Crawled : 06:00)
- prnewswire.com
BHVN
|
News
0 d
|
$42.16
-4.25%
0.85%
3.7M
|
Health Technology
|
-66.8%
|
O:
-4.12%
H:
3.2%
C:
3.11%
license
NURTEC® ODT Approved In Kuwait For Acute Treatment Of Migraine
Published:
2021-11-17
(Crawled : 14:30)
- biospace.com/
BHVN
|
News
0 d
|
$42.16
-4.25%
0.85%
3.7M
|
Health Technology
|
-63.25%
|
O:
-0.75%
H:
0.0%
C:
0.0%
treatment
migraine
approval
Biohaven Enrolls Phase 1a/1b Clinical Trial of BHV-1100, Lead Asset from its ARM™ (Antibody Recruiting Molecule) Platform, in Combination with NK Cell Therapy for the Treatment of Multiple Myeloma
Published:
2021-10-27
(Crawled : 12:00)
- prnewswire.com
BHVN
|
News
0 d
|
$42.16
-4.25%
0.85%
3.7M
|
Health Technology
|
-68.99%
|
O:
0.21%
H:
0.1%
C:
-3.26%
treatment
phase 1
therapy
antibody
trial
phase 1b
enroll
Biohaven Announces Preliminary 3Q2021 Net Product Revenue For NURTEC ODT, The First And Only Migraine Medication For Both Acute And Preventive Treatment
Published:
2021-10-05
(Crawled : 12:15)
- biospace.com/
BHVN
|
News
0 d
|
$42.16
-4.25%
0.85%
3.7M
|
Health Technology
|
-69.31%
|
O:
3.9%
H:
2.03%
C:
-3.89%
treatment
migraine
Biohaven Spotlights Nurtec® ODT (rimegepant), the only dual-therapy indicated for both the acute and preventive treatment of migraine, at the 2021 International Headache Society - European Headache Federation Joint Congress
Published:
2021-09-09
(Crawled : 12:00)
- biospace.com/
BHVN
|
News
0 d
|
$42.16
-4.25%
0.85%
3.7M
|
Health Technology
|
-66.71%
|
O:
-0.14%
H:
2.85%
C:
-0.58%
treatment
europe
migraine
therapy
Biohaven Announces Preliminary 2Q2021 Net Product Revenue For NURTEC ODT, The First And Only Migraine Medication For Both Acute And Preventive Treatment
Published:
2021-07-07
(Crawled : 12:00)
- biospace.com/
BHVN
|
News
0 d
|
$42.16
-4.25%
0.85%
3.7M
|
Health Technology
|
-55.63%
|
O:
16.08%
H:
2.25%
C:
-2.18%
treatment
migraine
ev
FDA Approves Biohaven's NURTEC® ODT (rimegepant) for Prevention: Now the First and Only Migraine Medication for both Acute and Preventive Treatment
Published:
2021-05-27
(Crawled : 22:00)
- biospace.com/
BHVN
|
News
0 d
|
$42.16
-4.25%
0.85%
3.7M
|
Health Technology
|
-45.81%
|
O:
-0.01%
H:
2.56%
C:
2.0%
treatment
fda
migraine
fda approval
National Headache Foundation Survey Shows Majority of People with Migraine are Unable to Control Disease and Dissatisfied with Current Preventive Treatment Options
Published:
2021-05-11
(Crawled : 12:00)
- prnewswire.com
BHVN
|
News
0 d
|
$42.16
-4.25%
0.85%
3.7M
|
Health Technology
|
-36.75%
|
O:
-3.94%
H:
6.79%
C:
5.79%
disease
treatment
migraine
Biohaven's NURTEC® ODT Approved In United Arab Emirates For Acute Treatment Of Migraine
Published:
2021-03-11
(Crawled : 14:00)
- biospace.com/
BHVN
|
News
0 d
|
$42.16
-4.25%
0.85%
3.7M
|
Health Technology
|
-42.24%
|
O:
2.38%
H:
4.18%
C:
2.68%
treatment
migraine
approval
Biohaven's NURTEC® ODT Approved In Israel For Acute Treatment Of Migraine
Published:
2021-03-10
(Crawled : 22:03)
- biospace.com/
BHVN
|
News
0 d
|
$42.16
-4.25%
0.85%
3.7M
|
Health Technology
|
-45.61%
|
O:
1.54%
H:
0.95%
C:
-7.25%
israel
treatment
migraine
approval
Biohaven's Rimegepant For Preventive Treatment Of Migraine Published In The Lancet
Published:
2020-12-16
(Crawled : 14:00)
- biospace.com/
BHVN
|
News
0 d
|
$42.16
-4.25%
0.85%
3.7M
|
Health Technology
|
-50.53%
|
O:
1.4%
H:
1.19%
C:
-0.28%
treatment
lancet
Gainers vs Losers
64%
36%
Top 10 Gainers
AGBA
|
News
|
$1.02
155.0%
57.94%
120M
|
Finance
ZCMD
|
$2.86
108.76%
52.1%
2.3M
|
Commercial Services
INVO
|
$1.555
104.6%
51.13%
5M
|
Health Technology
ISPC
|
$0.437
105.16%
49.53%
37M
|
Professional, Scientific, and T...
WLGS
|
News
|
$0.92
84.0%
45.65%
1.6M
|
OST
|
$0.499
21.38%
45.26%
1.9M
|
XPON
|
News
|
$3.1
60.62%
37.74%
17M
|
TIRX
|
$0.7
44.39%
30.74%
58M
|
BNTC
|
News
|
$6.92
44.17%
30.64%
3.5M
|
Health Technology
GGE
|
$0.035
19.86%
29.3%
64M
|
Your saved searches
Save your searches and get alerts when important news are released.